incidence, morbidity, mortality and organisms
Despite major advances in prevention and treatment, FN remains one of the most concerning complications of cancer chemotherapy, and is a major cause of morbidity, healthcare resource use and compromised efficacy resulting from delays and dose reductions in chemotherapy. Mortality from FN has diminished steadily but remains significant. Overall mortality rates are 5% in patients with solid tumours (1% in lowrisk patients) and as high as 11% in some haematological malignancies. Prognosis is worst in patients with proven bacteraemia, with mortality rates of 18% in Gram-negative and 5% in Gram-positive bacteraemia. Mortality varies according to the MASCC prognostic index (detailed further down): as low as 3% if the MASCC score is >21, but as high as 36% if the MASCC score is <15. Elderly patients are at a higher risk of febrile neutropenia following chemotherapy, with worse morbidity and mortality rates. However, good prospective trial data are lacking with respect to elderly cancer patients due to their relative exclusion from randomized clinical trials, which therefore limits specific recommendations relative to this patient group.
Positive microbiological detection rates by standard blood cultures vary depending on whether patients have had prophylactic antibiotics and whether they have a central venous catheter (CVC). One trial conducted in patients with solid tumours in which only a minority had CVCs (<10%) identified a rate of 7.2% in patients given antibiotic prophylaxis versus 14.6% in patients not given prophylaxis. Other trials in patients with haematological malignancies, with a higher proportion of patients with CVCs, report rates between 17% and 31%.
Different centres experience different patterns of principal causative pathogens. Consequently these guidelines are intended for use alongside local antimicrobial policies.
Over the last few decades a shift has occurred from FN associated mainly with Gram-negative bacteria to FN associated with Gram-positive organisms. Of those blood cultures that are positive in the setting of FN, typically 70% are reported to be Gram-positive organisms. An increase in antibiotic-resistant strains such as extended spectrum b-lactamase (ESBL)-producing Gram-negative bacteria, vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) has been noted. Increasing numbers of infections with fluconazole-resistant Candida strains (e.g. Candida krusei and Candida glabrata) have also been reported.
patient education and local policies
Success in FN management requires prompt recognition of, and reaction to, potential infection. Vital to this is educating outpatients to monitor symptoms including body temperature, and clear written instructions on when and how to contact the appropriate service in the event of concerns. In addition, effective written local policies are essential to ensure a rapid response whenever FN is suspected. Some patients may present with FN via the Emergency Department, and in this situation clear protocols must be in place to manage these patients appropriately.
initial assessment and investigations
A detailed history should be taken including the nature of the chemotherapy given, prior prophylactic antibiotic, concomitant steroid use, recent surgical procedure and presence of allergies. It is important to check the clinical record for past positive microbiology, in particular previous presence of antibiotic-resistant organisms or bacteraemia, in order to guide therapy.
An initial assessment (Table 1) of circulatory and respiratory function, with vigorous resuscitation where necessary, should be followed by careful examination for potential foci of infection. This is important because some infections (e.g. community-acquired pneumonia) may not be adequately covered by empirical antibiotics chosen for treating FN. Signs and symptoms of infection in neutropenic patients can be minimal particularly in those receiving corticosteroids. Vigilance is required in any patient at risk of FN who presents unwell, hypotensive, with a low grade temperature or afebrile, as they may be developing Gram-negative septicaemia, requiring prompt treatment.
Urgent full blood count to ascertain the neutrophil level along with other investigations listed in Table 1 are crucial in guiding early management.
Two sets of blood cultures from a peripheral vein and any indwelling venous catheters should be taken. In addition, sputum, urine, skin swabs and stool specimens where clinically indicated should be sampled, before the prompt institution of empirical broad-spectrum antimicrobial therapy.
outcome risk assessment
The vast majority of FN cases, as managed according to the algorithm set out in Figure 1 , respond promptly to empirical therapy, suffering no major complications. A number of instruments have been developed in attempts to predict those high-risk cases where complications are likely. The most widely used instrument, the Multinational Association for Supportive Care (MASCC) index allows the clinician to rapidly assess risk before access to neutrophil count and without knowledge of the burden of underlying cancer, and has been prospectively validated. The criteria and weighting scores are listed in Table 2 . Low-risk cases are those scoring ‡21. The serious medical complication rate in these is estimated to be 6% and mortality just 1%. However, some physicians are reluctant to use less vigorous management policies where there remains even a small risk of treatment-related death. If an obvious focus of infection is apparent, antibacterials should be tailored accordingly.
low-risk patients oral therapy
A recent review has concluded that inpatient oral antibacterial therapy can be safely substituted for conventional intravenous (i.v.) treatment in some low-risk FN patients, namely those who are haemodynamically stable, who do not have acute leukaemia or evidence of organ failure, who do not have pneumonia, an indwelling venous catheter or severe soft tissue infection [I, A]. Precise criteria were not defined as they 
specific indications for alternative therapy
Apart from the standard treatment with broad-spectrum antibacterial agents, there are a number of situations in clinical practice that require a specific regimen. The duration of treatment may vary and local antibacterial guidelines should be followed in these circumstances. antibiotics, and the need for catheter removal. When CRI is suspected, and the patient is stable, the catheter should not be removed without microbiological evidence of infection. A glycopeptide such as vancomycin should be administered through the line when possible to cover Gram-positive organisms [III, A]. Teicoplanin is a useful alternative as it can be administered once daily as a line lock. Success in treating CRI without removing the catheter depends on the pathogen isolated in the blood cultures.
In CRI due to coagulase-negative Staphylococcus (CNS), an attempt at preserving the catheter can be made if the patient is stable [III, B] . A prospective cohort study of antibiotictreated CNS bacteraemia in neonates with CVCs found that retention of the line was successful in 46% of cases. A recent retrospective study in adults reported a 93% success rate in treating CRIs caused by CNS, with a re-infection rate over the following 4 months of only 8%. Catheter retention did not impact on the resolution of CNS bacteraemia but was a significant risk factor for recurrence in those patients who had the catheter retained.
Removal of the line is indicated in the context of tunnel infections, pocket infections (implanted port system) [III, B], persistent bacteraemia despite adequate treatment, atypical mycobacterial infection and candidaemia. With regard to line infections caused by S. aureus, the literature is divided. A recent German review recommends that line removal is mandatory whilst a retrospective Korean cohort study reported a 50% success rate in line salvage with anti-staphylococcal antibiotics. The desire to preserve the line must be balanced against the risk of metastatic spread by bloodstream seeding. The recommendation should be to remove the line if at all possible, whilst recognizing that with careful management it might be possible to maintain it for a short period. Persistent fever and bacteraemia despite appropriate antibiotics are indications for line removal. candidiasis. Patients at risk of disseminated candidiasis are those with prolonged neutropenia and therefore mostly those with haematological malignancies undergoing myeloablative therapy. Candidaemia can be diagnosed on blood culture; however, cultures may take several days to become positive. Therefore treatment is usually started empirically in patients whose fever fails to respond to broad-spectrum antibiotics after 3-7 days of appropriate treatment. A chest computed tomography (CT) scan including liver and spleen should be performed before commencing anti-Candida treatment, looking for typical changes.
First-line empirical treatment depends on what is known about the patient. Liposomal amphotericin B or an echinocandin antifungal such as caspofungin are appropriate first-line treatment if the patient has already been exposed to an azole or if the patient is known to be colonized with nonalbicans Candida [I, A]. Fluconazole can be given first line provided the patient is at low risk of invasive aspergillosis, local epidemiological data suggest low rates of azole-resistant isolates of Candida and the patient has not received an azole antifungal as prophylaxis. Once begun, antifungal treatment should be continued until neutropenia has resolved, or for at least 14 days in patients with a demonstrated fungal infection.
lung infiltrates. Patients with acute myeloid leukaemia during remission induction chemotherapy and those undergoing allogeneic haematopoietic stem cell transplantation with prior conditioning chemotherapy are at risk of invasive aspergillosis due to prolonged and profound neutropenia. Frequent assessment of initial response to antibacterial therapy is essential and in the absence of prompt improvement, further investigations are warranted. If invasive aspergillus is suspected, a high-resolution chest CT scan should be performed the same day, looking for typical features such as nodules with haloes or ground-glass change. If any infiltrate is found, bronchoalveolar lavage should be undertaken if possible. Advice from an infectious diseases (ID) specialist or clinical microbiologist is advised, and appropriate therapy against infection with fungi or Pneumocystis species should be instituted. Choices of antifungal agents will depend on centres, individual patients and use of prior prophylactic therapy. daily follow-up and assessment of response
The frequency of clinical assessment is determined by severity, but may be required every 2-4 h in cases needing resuscitation. Daily assessment of fever trends, bone marrow and renal function is indicated until the patient is apyrexial and ANC ‡0.5 · 10 9 /l ( Figure 2 ). Repeated imaging may be required in patients with persistent pyrexia.
If apyrexial and ANC ‡0.5 · 10 9 /l at 48 h. 
duration of therapy
If the neutrophil count is ‡0.5 · 10 9 /l, the patient is asymptomatic and has been afebrile for 48 h and blood cultures are negative, antibacterials can be discontinued [II, A] .
If the neutrophil count is £0.5 · 10 9 /l, the patient has suffered no complications and has been afebrile for 5-7 days, antibacterials can be discontinued except in certain high-risk cases with acute leukaemia and following high-dose chemotherapy when antibacterials are often continued for up to 10 days, or until the neutrophil count is ‡0. 
